Trick or Treat: Unmasking Antibody Reproducibility in Life Sciences

In this webinar, you will learn:

• How mAb irreproducibility could unknowingly impact your research outcomes
• Proven strategies to mitigate reproducibility risks when using research reagents
• The role of antibody sequencing in ensuring reproducibility with mAbs
• Rapid, cost-effective sequence confirmation for routine applications
• The next frontier: polyclonal antibody sequencing and recombinant pAbs

Researchers often purchase antibodies expecting reliability, only to face failed experiments, irreproducible results, and wasted time and money. Nearly 50% of commercial antibodies fail to meet basic characterization standards, resulting in an estimated $0.4–1.8 billion in annual losses in the U.S.

Monoclonal antibodies (mAbs) produced in hybridomas and polyclonal antibodies (pAbs) produced from immunized animal serum have significant drawbacks. We have seen it all – additional productive chains, oligoclonal-like mAbs, batch-to-batch variability, all of which contribute to misleading results and irreproducible research.

To combat this, using sequence-defined recombinantly produced antibodies ensures consistency in binding and behavior due to their characterized sequences.

We will present case studies demonstrating how techniques like mAb sequencing, antibody sequence confirmation, and pAb conversion can enhance research reliability.

Speaker Bios